Annual Cash & Cash Equivalents
$22.35 M
-$10.20 M-31.33%
31 December 2023
Summary:
Lyra Therapeutics annual cash & cash equivalents is currently $22.35 million, with the most recent change of -$10.20 million (-31.33%) on 31 December 2023. During the last 3 years, it has fallen by -$52.24 million (-70.03%). LYRA annual cash & cash equivalents is now -70.03% below its all-time high of $74.59 million, reached on 31 December 2020.LYRA Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$23.80 M
-$8.11 M-25.40%
30 September 2024
Summary:
Lyra Therapeutics quarterly cash and cash equivalents is currently $23.80 million, with the most recent change of -$8.11 million (-25.40%) on 30 September 2024. Over the past year, it has dropped by -$1.05 million (-4.23%). LYRA quarterly cash and cash equivalents is now -80.28% below its all-time high of $120.67 million, reached on 30 June 2022.LYRA Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LYRA Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -31.3% | -4.2% |
| 3 y3 years | -70.0% | -59.1% |
| 5 y5 years | -6.4% | - |
LYRA Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -70.0% | at low | -80.3% | +50.6% |
| 5 y | 5 years | -70.0% | +127.9% | -80.3% | +142.7% |
| alltime | all time | -70.0% | +127.9% | -80.3% | +142.7% |
Lyra Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $23.80 M(-25.4%) |
| June 2024 | - | $31.91 M(+101.9%) |
| Mar 2024 | - | $15.80 M(-29.3%) |
| Dec 2023 | $22.35 M(-31.3%) | $22.35 M(-10.0%) |
| Sept 2023 | - | $24.85 M(-54.3%) |
| June 2023 | - | $54.36 M(+146.9%) |
| Mar 2023 | - | $22.02 M(-32.4%) |
| Dec 2022 | $32.55 M | $32.55 M(-70.3%) |
| Sept 2022 | - | $109.56 M(-9.2%) |
| June 2022 | - | $120.67 M(+257.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $33.76 M(-26.2%) |
| Dec 2021 | $45.75 M(-38.7%) | $45.75 M(-21.3%) |
| Sept 2021 | - | $58.13 M(-15.8%) |
| June 2021 | - | $69.05 M(+4.4%) |
| Mar 2021 | - | $66.11 M(-11.4%) |
| Dec 2020 | $74.59 M(+660.5%) | $74.59 M(-8.5%) |
| Sept 2020 | - | $81.56 M(-5.8%) |
| June 2020 | - | $86.60 M(+145.7%) |
| Mar 2020 | - | $35.25 M(+259.4%) |
| Dec 2019 | $9.81 M(-58.9%) | $9.81 M |
| Dec 2018 | $23.89 M | - |
FAQ
- What is Lyra Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Lyra Therapeutics?
- What is Lyra Therapeutics annual cash & cash equivalents year-on-year change?
- What is Lyra Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Lyra Therapeutics?
- What is Lyra Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Lyra Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of LYRA is $22.35 M
What is the all time high annual cash & cash equivalents for Lyra Therapeutics?
Lyra Therapeutics all-time high annual cash & cash equivalents is $74.59 M
What is Lyra Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, LYRA annual cash & cash equivalents has changed by -$10.20 M (-31.33%)
What is Lyra Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of LYRA is $23.80 M
What is the all time high quarterly cash and cash equivalents for Lyra Therapeutics?
Lyra Therapeutics all-time high quarterly cash and cash equivalents is $120.67 M
What is Lyra Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, LYRA quarterly cash and cash equivalents has changed by -$1.05 M (-4.23%)